A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
A Phase 1 Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases
Sponsor: Kite, A Gilead Company
This observational or N/A phase trial investigates Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis and is currently actively recruiting participants. Kite, A Gilead Company leads this study, which shows 4 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
Apr 21, 2026 — Present [daily]
Recruiting
Status: Not Yet Recruiting → Recruiting · Phase: PHASE1 → None
-
Mar 2026 — Apr 2026 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.
Contact Information
- Kite, A Gilead Company
For direct contact, visit the study record on ClinicalTrials.gov .